Abstract
In a double-blind, random-assignment, parallel-group trial, outpatients with major depression received either the new antidepressant clovoxamine, the tricyclic amitriptyline, or placebo for 6 weeks. By an "improvement" criterion of 50% or greater improvement in the Hamilton Depression Scale (HAM-D) total score, 88% of clovoxamine completers improved versus 75% with amitriptyline and 43% with placebo; however, due to small numbers, the differences failed to reach statistical significance. Diminished salivary flow was significantly greater with amitriptyline, as were complaints of dry mouth, somnolence, dizziness, and headache. Nausea and vomiting were more common in the clovoxamine-treated group. With amitriptyline, but not with clovoxamine, memory performance declined over a month. However, psychomotor performance was not affected.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 307-314 |
| Number of pages | 8 |
| Journal | Comprehensive Psychiatry |
| Volume | 31 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1990 |
Funding
From the Departments of Psychiatry, University of Arizona College of Medicine. Tucson, AZ; Massachusetts General Hospital, Harvard Medical School, and The Chicago Medical School. Supported by Kali-Duphar Laboratories, Inc. and The Arbour Research Foundation. Address reprint requests to Alan J. Gelenberg, M.D., Department of Psychiatry, University of Arizona, Health Sciences Center, 1501 N Campbell Ave. Tucson, AZ 84724. ID1 990 by W.B. Saunders Company. 0010-440x/90/3104-0004$03.00/0
ASJC Scopus subject areas
- Clinical Psychology
- Psychiatry and Mental health